The law change removes the federal requirement for practitioners to have a DATA-Waiver registration to prescribe buprenorphine for the treatment of opioid use disorder.
The medication is a non-steroidal anti-inflammatory drug indicated for the acute treatment of migraine attacks with or without aura, in adults 18 years of age or older.
Leana Salamah, vice president of marketing at the International Housewares Association, discusses how drug stores have always been a purveyor of curative wellness for consumers.
